Veru INC. (VERU) — SEC Filings

Overview

Veru INC. (VERU) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 16, 2026: Veru Inc. filed an EFFECT form on April 16, 2026, indicating the effectiveness of a registration statement. The effectiveness date is April 15, 2026. The filing is related to Act 33 and has File No. 333-294909.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 8 bearish, 41 neutral, 1 mixed. The dominant filing sentiment for Veru INC. is neutral.

Filing Type Overview

Veru INC. (VERU) has filed 2 EFFECT, 1 S-3, 2 10-K, 25 8-K, 5 10-Q, 6 DEFA14A, 2 DEF 14A, 3 SC 13G/A, 3 SC 13G, 1 10-K/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• EFFECT Filing — EFFECT · Apr 16, 2026
• Veru Inc. (VERU) Registration Statement Declared Effective — EFFECT · Apr 16, 2026 Risk: medium
  Veru Inc. filed an EFFECT form on April 16, 2026, indicating the effectiveness of a registration statement. The effectiveness date is April 15, 2026. The filing
• Veru Inc. Files S-3 Registration Statement — S-3 · Apr 7, 2026 Risk: medium
  Veru Inc. filed an S-3 registration statement on April 7, 2026, indicating plans to offer and sell securities. The filing details the company's business, financ
• Veru Shifts Focus to Cardiometabolic Drugs, Divests FC2 Business — 10-K · Dec 17, 2025 Risk: high
  VERU INC. (VERU) is a late clinical stage biopharmaceutical company focused on developing novel medicines for cardiometabolic and inflammatory diseases, as deta
• 8-K Filing — 8-K · Dec 17, 2025
• Veru Inc. Files 8-K for Material Agreement — 8-K · Oct 30, 2025 Risk: medium
  Veru Inc. filed an 8-K on October 30, 2025, reporting an entry into a material definitive agreement and other events. The filing also includes financial stateme
• Veru Inc. Terminates Material Definitive Agreement — 8-K · Sep 26, 2025 Risk: medium
  Veru Inc. filed an 8-K on September 26, 2025, reporting the termination of a material definitive agreement as of September 22, 2025. The filing also includes fi
• Veru Inc. Files 8-K Under 'Other Events' — 8-K · Aug 27, 2025 Risk: medium
  Veru Inc. filed an 8-K on August 27, 2025, reporting an event that occurred on August 26, 2025. The filing is categorized under 'Other Events' and does not prov
• VERU's Q3 Losses Persist Amidst Stagnant Financials — 10-Q · Aug 12, 2025 Risk: high
  VERU INC. reported a net loss of $14,868,762 for the nine months ended June 30, 2025, compared to a net loss of $14,856,762 for the same period in 2024, indicat
• Veru Inc. Files 8-K on Financials — 8-K · Aug 12, 2025 Risk: low
  Veru Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The fil
• Veru Inc. Files 8-K on Security Holder Vote Matters — 8-K · Jul 25, 2025 Risk: low
  Veru Inc. filed an 8-K on July 25, 2025, to report on the submission of matters to a vote of its security holders. The filing does not contain specific details
• Veru Inc. Files Proxy Materials — DEFA14A · Jul 15, 2025 Risk: low
  Veru Inc. filed a Definitive Additional Materials proxy statement on July 15, 2025. This filing relates to the company's proxy materials, which are typically us
• VERU Seeks Shareholder Nod for 1-for-20 Reverse Stock Split — DEF 14A · Jun 10, 2025 Risk: medium
  VERU INC. has filed a Definitive Proxy Statement (DEF 14A) on June 10, 2025, to hold a Special Meeting of Shareholders on July 25, 2025, at 9:00 a.m. local time
• Veru Inc. Reports Q2 2025 Financials — 10-Q · May 8, 2025 Risk: medium
  Veru Inc. filed its 10-Q for the period ending March 31, 2025, reporting a net loss for the quarter. The company's total assets were $148.8 million as of March
• Veru Inc. Files 8-K on Financials — 8-K · May 8, 2025 Risk: low
  Veru Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition, and providing financial statements and exhibits. The comp
• Veru Inc. Files 8-K: Director Changes & Officer Compensation — 8-K · Mar 14, 2025 Risk: medium
  Veru Inc. filed an 8-K on March 14, 2025, reporting on the departure of directors, election of new directors, and compensatory arrangements for officers. The fi
• Veru Inc. Faces Potential NASDAQ Delisting — 8-K · Feb 28, 2025 Risk: high
  Veru Inc. filed an 8-K on February 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicates po
• Veru Inc. Q1 2025 Financials: Assets $148.6M, Equity $146.4M — 10-Q · Feb 13, 2025 Risk: low
  Veru Inc. reported its first quarter results for the period ending December 31, 2024. The company's total assets were $148,567,624, with total liabilities of $2
• Veru Inc. Files 8-K on Financials — 8-K · Feb 13, 2025 Risk: low
  Veru Inc. filed an 8-K on February 13, 2025, reporting on its results of operations and financial condition, and including financial statements and exhibits. Th
• Veru Inc. Files Definitive Proxy Statement — DEF 14A · Jan 28, 2025 Risk: low
  Veru Inc. filed its definitive proxy statement on January 28, 2025, for its annual meeting of stockholders. The filing, designated as DEF 14A, outlines the info
• Veru Inc. Reports Material Agreements, Asset Changes — 8-K · Jan 3, 2025 Risk: medium
  Veru Inc. filed an 8-K on January 3, 2025, reporting events as of December 30, 2024. The filing indicates the entry into and termination of material definitive
• Veru Inc. Reports FY24 Results: $148.6M Assets, $93.9M Net Loss — 10-K · Dec 16, 2024 Risk: medium
  Veru Inc. filed its 10-K for the fiscal year ending September 30, 2024, reporting total assets of $148.6 million and total liabilities of $2.2 million. The comp
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• SC 13G Filing — SC 13G · Oct 24, 2024
• Veru Inc. Signs Material Definitive Agreement — 8-K · Sep 20, 2024 Risk: medium
  Veru Inc. entered into a material definitive agreement on September 19, 2024. The company, previously known as The Female Health Co. and Wisconsin Pharmacal Com
• Veru Inc. Faces Nasdaq Delisting Warning — 8-K · Aug 30, 2024 Risk: high
  Veru Inc. announced on August 29, 2024, that it received a notification from Nasdaq regarding its failure to meet the minimum bid price requirement for continue
• Veru Inc. Terminates Material Definitive Agreement — 8-K · Aug 23, 2024 Risk: medium
  Veru Inc. announced on August 19, 2024, the termination of a material definitive agreement. The company, formerly known as Female Health Co. and Wisconsin Pharm
• Veru Inc. Q3 2024: Net Loss of $2.2M, Assets $148.6M — 10-Q · Aug 8, 2024 Risk: medium
  Veru Inc. reported its third quarter fiscal year 2024 results ending June 30, 2024. The company's total assets were $148.6 million, with total liabilities of $2
• Veru Inc. Files 8-K on Operations and Financials — 8-K · Aug 8, 2024 Risk: medium
  Veru Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The fili
• Veru Inc. Appoints New Directors, Reports Executive Compensation — 8-K · Aug 2, 2024 Risk: medium
  Veru Inc. announced on August 1, 2024, a change in its board of directors, with Dr. Laura L. Wingate and Dr. Richard A. U. Smith joining the board. Additionally
• Veru Inc. Files 8-K on Shareholder Vote Matters — 8-K · Jul 2, 2024 Risk: low
  Veru Inc. filed an 8-K on July 2, 2024, reporting on matters submitted to a vote of security holders as of June 27, 2024. The filing details the company's corpo
• Veru Inc. Reports on Shareholder Meeting — 8-K · Jun 21, 2024 Risk: low
  Veru Inc. filed an 8-K on June 21, 2024, reporting on a shareholder meeting held on June 18, 2024. The primary purpose was to vote on matters presented to secur
• Veru Inc. Files Additional Proxy Materials — DEFA14A · Jun 20, 2024 Risk: low
  Veru Inc. filed a Definitive Additional Materials proxy statement on June 20, 2024. This filing relates to the company's Schedule 14A, indicating it's providing
• Veru Inc. Proxy Statement Filed — DEFA14A · Jun 18, 2024 Risk: low
  Veru Inc. filed a Definitive Additional Materials proxy statement on June 18, 2024. This filing relates to the company's annual meeting of stockholders, where p
• Veru Inc. Appoints PricewaterhouseCoopers as New Auditor — 8-K · May 22, 2024 Risk: low
  Veru Inc. announced on May 16, 2024, that it has appointed PricewaterhouseCoopers LLP as its new independent registered public accounting firm. This change foll
• Veru Inc. Files Proxy Statement Amendment — DEFA14A · May 9, 2024 Risk: low
  Veru Inc. filed a Definitive Additional Materials proxy statement on May 9, 2024. This filing relates to the company's annual meeting and is an amendment to pre
• Veru Inc. Files 8-K on Financials — 8-K · May 8, 2024 Risk: low
  Veru Inc. filed an 8-K on May 8, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The
• Veru Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: medium
  VERU INC. (VERU) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Veru Inc. filed its 10-Q report for the period ending March 31, 2024. The filing d
• Veru Inc. Files 8-K: Material Definitive Agreement — 8-K · Apr 26, 2024 Risk: medium
  Veru Inc. entered into a Material Definitive Agreement on April 24, 2024. The company, previously known as FEMALE HEALTH CO and WISCONSIN PHARMACAL COMPANY INC,
• Veru Inc. Raises $25M in Private Placement — 8-K · Apr 25, 2024 Risk: medium
  Veru Inc. announced on April 23, 2024, that it has entered into a securities purchase agreement with institutional investors for a private placement. The compan
• SC 13G Filing — SC 13G · Apr 24, 2024
• Veru Inc. Files Proxy Materials — DEFA14A · Apr 1, 2024 Risk: low
  Veru Inc. filed a Definitive Additional Materials proxy statement on April 1, 2024. This filing relates to the company's proxy materials, which are typically us
• Veru Inc. Files Amended 10-K for Fiscal Year Ended September 30, 2023 — 10-K/A · Apr 1, 2024 Risk: low
  VERU INC. (VERU) filed a Amended Annual Report (10-K/A) with the SEC on April 1, 2024. Veru Inc. filed an amended 10-K for the fiscal year ending September 30,
• Veru Inc. Files Definitive Proxy Statement — DEFA14A · Mar 22, 2024 Risk: low
  Veru Inc. filed a Definitive Proxy Statement (DEFA14A) on March 22, 2024. This filing is a standard proxy statement, indicating it's related to shareholder voti
• VERU INC. Receives Notice of Delisting or Listing Standard Failure — 8-K · Feb 28, 2024 Risk: high
  VERU INC. filed an 8-K on February 28, 2024, reporting an event that occurred on February 21, 2024. The filing indicates the company received a "Notice of Delis
• VERU INC. Discloses Non-Reliance on Past Financial Statements — 8-K · Feb 15, 2024 Risk: high
  VERU INC. filed an 8-K on February 15, 2024, under Item 4.02, disclosing non-reliance on previously issued financial statements or a related audit report or com
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• VERU INC. Files 8-K on Financial Results and Operations — 8-K · Feb 8, 2024 Risk: low
  VERU INC. filed an 8-K on February 8, 2024, to report an event related to its financial condition and operations. This filing, under Items 2.02 and 9.01, indica

Frequently Asked Questions